Want to see SEED full AI Analyst Report?
SEED Stock Chart & Stats
$1.32
-$0.10(-5.19%)
At close: 4:00 PM EST
$1.32
-$0.10(-5.19%)
Day’s Range― - ―
52-Week Range$0.91 - $2.49
Previous CloseN/A
Volume43.60K
Average Volume (3M)2.25M
Market Cap
$12.39M
Enterprise Value$14.71
Total Cash (Recent Filing)$13.37M
Total Debt (Recent Filing)$29.12M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Jan 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.40
Shares Outstanding12,143,526
10 Day Avg. Volume6,011,928
30 Day Avg. Volume2,246,586
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-2.76
Price to Sales (P/S)0.71
P/FCF Ratio-1.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Large R&D & Breeding PipelineA deep, data-driven breeding pipeline (30k+ test crosses, 10k+ new combinations, AI applied to 200k+ germplasm) materially increases the probability of a steady flow of commercially viable varieties and biotech traits. This breadth creates sustained product optionality, supports licensing, and raises barriers to entry over multi-year commercialization horizons.
Biotech Credentials & Commercial ReadinessHolding a biosafety certificate, integrating gene-editing tools, restoring processing capacity and forming a breeding service consortium materially shorten time-to-market for GMO/gene-edited traits. These capabilities enable commercialization and non-seed service revenue streams, reducing single-product dependency and strengthening long-term go-to-market readiness.
Cost Discipline And Improved Operating EfficiencySubstantial, durable cost-cutting (total OPEX -43.9%, G&A -69.8%) combined with a meaningful reduction in operating loss signals a leaner cost structure. If sustained, this improves cash burn dynamics, extends runway for commercialization investments, and increases the chance that incremental revenue converts to positive operating leverage over the next 2–3 years.
Bears Say
Stressed Balance SheetNegative equity combined with a notable debt increase in 2025 materially reduces financial flexibility and raises refinancing and dilution risks. With total assets contracting and liabilities elevated, the company has limited balance-sheet capacity to fund commercialization or withstand delays in revenue realization, making long-term execution riskier.
Weak Cash GenerationPersistent negative operating and free cash flow through 2023–2025 means the business does not self-fund growth and is dependent on external capital. This weak cash generation constrains sustained R&D and route-to-market investment, raises liquidity vulnerability, and increases the chance that promising pipeline progress cannot be commercialized without fresh funding.
Revenue Decline & Regulatory/Execution DependencyA sharp revenue decline (~31.9% YoY) amid a strategic product shift highlights near-term top-line fragility. Future growth depends on converting the breeding pipeline into sales and on regulatory approvals for GMO traits; both are timing-sensitive. This dual dependency creates structural uncertainty around sustained revenue and cash-flow recovery.
Origin Agritech News
SEED FAQ
What was Origin Agritech Limited’s price range in the past 12 months?
Origin Agritech Limited lowest stock price was $0.91 and its highest was $2.49 in the past 12 months.
What is Origin Agritech Limited’s market cap?
Origin Agritech Limited’s market cap is $12.39M.
When is Origin Agritech Limited’s upcoming earnings report date?
Origin Agritech Limited’s upcoming earnings report date is Jan 11, 2027 which is in 173 days.
How were Origin Agritech Limited’s earnings last quarter?
Origin Agritech Limited released its earnings results on May 21, 2026. The company reported -$0.172 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Origin Agritech Limited overvalued?
According to Wall Street analysts Origin Agritech Limited’s price is currently Overvalued.
Does Origin Agritech Limited pay dividends?
Origin Agritech Limited does not currently pay dividends.
What is Origin Agritech Limited’s EPS estimate?
Origin Agritech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Origin Agritech Limited have?
Origin Agritech Limited has 12,143,526 shares outstanding.
What happened to Origin Agritech Limited’s price movement after its last earnings report?
Origin Agritech Limited reported an EPS of -$0.172 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Origin Agritech Limited?
Currently, no hedge funds are holding shares in SEED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Origin Agritech Limited
Established in 1997 and headquartered in Beijing, China, Origin Agritech Limited is a Chinese firm operating in two primary areas: agricultural biotechnology and an e-commerce platform. Its biotechnology segment focuses on the genetic enhancement and breeding of crop seeds, encompassing the development, production, and distribution of hybrid crop varieties and associated seed technologies. The firm also manages an e-commerce platform that caters to farmers across China, offering a diverse array of goods via online and mobile channels. This selection includes agricultural seeds like corn, rice, and vegetables, along with essential farming inputs such as fertilizers and agricultural chemicals. Additionally, the platform provides food, household items, and other consumer products. Origin Agritech maintains collaboration agreements with esteemed institutions such as the Chinese Academy of Agricultural Sciences, the National Maize Improvement Center, China Agricultural University, and Zhejiang University.
Technical Analysis
American Vanguard
―
Arcadia Biosciences
―
BioHarvest Sciences
―
Bioceres Crop Solutions
―
―
Ownership Overview
―
Insiders
0.07% Mutual Funds
0.33% Other Institutional Investors
99.60% Public Companies and
Individual Investors